We have previously shown that Mycoplasma arthritidis produces a soluble T-cell mitogen (MAM) which is active for most mouse strains that express the alpha chain of the I-E molecule (EB) encoded within the murine major histocompatibility complex. The lymphocytes from mice injected intravenously with the MAM exhibited a marked decrease in their ability to respond in vitro to MAM, to phytohemagglutinin, or to concanavalin A T-cell mitogens. Suppression could only be induced in MAM-responsive mouse strains and was most marked 1 to 4 days postinjection. Splenic and node cells and, to a lesser extent, thymic cells from MAM-injected mice could inhibit the ability of lymphocytes from normal mice to respond to MAM and lectin mitogens. A minimum of 2.5 x 104 viable cells was required for significant transfer of suppression, and no major histocompatibility complex restrictions were seen. Unlike concanavalin A-induced suppressor cells, which consist of a CD4-, CD8+ T-cell subset, suppressor cells induced by MAM were due to a CD4+ CD8-subset. We hypothesize that MAM may play a role in M. arthritidis-mediated disease by both its inflammatory and immunosuppressive properties.
Louis, Mo.) per ml, and 1:10,000 and 1:50,000 dilutions of MAS-P.
After 48 h of incubation at 37°C in 5% C02, 0.025 ml of medium containing 1 ,Ci of [3H]thymidine ([3H]TdR) (2 Ci/mM; Dupont, NEN Research Products, Boston, Mass.) was added and the lymphocytes were incubated for an additional 24 h before being harvested on a cell harvester (Skatron; Flow Laboratories, Inc., McLean, Va.). The resulting filter disks were transferred to minivials (Beckman Instruments, Inc., Fullerton, Calif.) containing Ready-Solve EP liquid scintillation cocktail (Beckman) and counted on a Beckman LS7800 counter. The results were expressed as the mean counts per minute, minus background, of triplicate determinations for which replicates were within a 30% range.
Antibodies. The GK 1.5 (L3T4/CD4), ADH 4.15 (Lyt2.2/ CD8), and 30-H12 (Thyl.2) monoclonal antibody (MAb)-producing cell lines were obtained courtesy of Barbara Araneo (Department of Medicine, University of Utah).
Depletion of lymphocyte subsets. A 107-cells per ml concentration of splenic lymphocytes was incubated in RPMI 1640 medium at 37°C in the presence of complement alone, with a 1:10 dilution of Cedarlane Low-Tox-M rabbit complement (Accurate Chemical Corp., Westbury, N.Y.), or with complement plus antibody to Thyl.2, CD4, or CD8 markers. After the incubation, the cells were washed three times in medium and each individual cell suspension was resuspended to 2.5 x 105 cells per well based on the cell counts of the complement control.
Flow cytometry. After complement depletion of lymphocyte subsets, portions from each sample were used in flow cytometry analysis for determination of the effectiveness of subset elimination. After quantitation of cells, 2 x 106 cells were washed by centrifugation in 0.2% sodium azide in PBS.
The pellets of the individual samples were suspended in 50 RI of goat serum (GIBCO Laboratories, Grand Island, N.Y.) and incubated for 30 min at room temperature to minimize nonspecific binding of the goat anti-mouse or goat anti-rat immunoglobulin G conjugated with fluorescein isothiocyanate. Cells were then washed three times, and the pellets were suspended in 200 ,ul of a 1:50 dilution of culture supernatant containing MAb to CD4 or Thyl.2 or ascites fluid containing MAb to CD8. After incubation at room temperature for 30 min followed by three washes, a 1:50 dilution of goat anti-mouse immunoglobulin G conjugated with fluorescein isothiocyanate (Sigma) was added to the MAb-treated cells and allowed to incubate for 30 min at 4°C. The samples were then washed three times and suspended in 1 ative responses to the mitogens depended on the dose of MAS-P given. Maximum inhibition was seen with 1:2 to 1:10 dilutions, although significant suppression (approximately 50%) was still seen at a 1:100 dilution. Boiled MAS-P, which lost >90% of its mitogenic activity, failed to induce significant suppression when injected into mice (data not shown). obtained with lymphocytes from PBS-injected control mice ( Fig. 3) . Maximum inhibition for all mitogens was seen 2 days postinjection, after which there was a gradual restoration of responses. By 8 days, the responses to PHA were essentially normal, and by 10 days, responses to ConA were near normal. The proliferative responses to MAS-P were still only 40 to 45% of control values at 10 days (Fig. 3) . In vitro transfer of suppression. The results observed above might be due to a direct toxic effect of MAM on immune cell functions or to the active induction of MAMmediated suppressor cells. To distinguish these possibilities, we examined the ability of MAM-induced hyporeactive cells to transfer suppression to normal cells.
BALB/c or C3H mice were injected i.v. with MAS-P or PBS, and after 48 h, splenocytes were collected and tested alone or in combination for their responses to MAS and MAS-P (Table 1) . In both experiments, lymphocytes from MAS-P-injected animals not only exhibited depressed responses to MAS or MAS-P but also actively suppressed the mitogenic responses of lymphocytes from PBS-injected controls by 68.9 to 94%. In a separate experiment, lymphocytes from MAM-nonresonder C3H.SW mice previously injected with MAS-P failed to suppress the response of normal C3H splenocytes to MAS-P (data not shown). Subsequently (Fig.   4 ), we demonstrated that at least 2.5 x 104 suppressor splenocytes or node cells were required for significant inhibition of MAS-P responses of normal splenocytes. Thymocytes collected from MAS-P-injected mice were largely ineffective in suppressing splenocyte responses subsequent to exposure to MAS-P. Similar results were obtained when we examined the effect of MAS-P-induced splenic or nodal suppressor cells on the responsiveness of normal cells to ConA (Fig. 5) induced suppression was MHC restricted. C3H (H-2k) mice were injected with MAS-P or with PBS. After 48 h, splenocytes were collected and tested for responsiveness to PHA and ConA and for their ability to suppress the responses of C3H (H-2k), C3H.SW (H-2"), and BALB/c (H-2d) splenocytes to PHA and ConA ( Table 2) . As seen before, splenocytes from MAS-P-injected C3H mice responded poorly to lectin mitogens in comparison with those from mice injected with PBS. Splenocytes from MAS-P-injected C3H mice but not those from PBS-injected mice suppressed the responses of normal C3H, C3H.SW, and BALB/c splenocytes to PHA and ConA. We conclude that suppressor splenocytes induced by MAM are not MHC restricted (Table 2) .
We next tested whether viable functional cells were required to transfer suppression. BALB/c mice were injected with MAS-P or with PBS, and splenocytes were harvested 48 h later. These splenocytes were untreated or treated with 2,500 rads -y of irradiation or fixed with 1% paraformaldehyde for 5 min prior to addition to splenocytes from normal untreated mice. Splenocytes from MAS-P-injected mice exhibited impaired responses to T-cell mitogens and significantly suppressed the ability of normal splenocytes to respond to mitogens ( In Table 4 , we demonstrate that the suppressor activity of splenocytes from mice injected with MAS-P is eliminated by treatment with anti-Thyl and complement and also with anti-CD4 and complement, suggesting that suppression is mediated by means of T cells, more specifically TH cells. Anti-Thyl antibody treatment of suppressor cells restored activity as before, but treatment with anti-CD8 antibody had Normal Cells alone no effect on the suppressor activity ( However, responses to PHA and ConA were restored to normal 8 and 10 days postinjection, respectively. Although high doses of MAM resulted in toxicity to the mice, immunosuppression was still seen at apparently nontoxic doses of MAM.
Despite the marked splenomegaly seen in MAM-injected mice, there was no marked difference in most experiments between the levels of spontaneous [3H]TdR uptake by splenocytes from MAM-injected mice compared with those from PBS-injected mice. This could be due in part to the presence of large numbers of blast cells. In addition, the suppressor circuit would be well established after the 1 to 3-day in vivo interaction of MAM with lymphocytes followed by the 3-day in vitro incubation to detect uptake of [3H]TdR.
The suppressive effects induced by MAM appear not to be related to the in vitro inhibition of lymphocyte proliferation mediated by live mycoplasmas or mycoplasmal extracts (3, 21) . In these cases, the inhibition is due to arginine depletion from culture media by the action of arginine deiminase, which is produced by many mycoplasmas including M. arthritidis (3, 21, 31, 32) .
The mechanism of the suppressive effect of in vivo MAM administration remains to be defined. First, it is unlikely that inhibition of lymphocyte responses is due to a direct toxic effect of MAM on host cell functions since suppressor effector cells were detected which could transfer hyporeactivity to normal untreated cells. Furthermore, only viable suppressor cells exhibited this property. The marked lymphadenopathy and splenomegaly seen suggested the occurrence of an active phase of lymphocyte proliferation. Such a marked activation could lead to liberation of lymphotoxins or suppressor factors which might be toxic for or regulate normal T-cell functions.
It is not unlikely that the suppressor cells generated in MAM-injected mice have cytotoxic potential. Earlier studies in our laboratory demonstrated that M. arthritidis organisms (1) and MAS (B. C. Cole and G. J. Sullivan, unpublished observations) could induce mouse splenocytes to become cytotoxic for syngeneic or allogeneic fibroblast target cells. We showed later that the cytotoxicity reaction was haplotype specific as for lymphocyte proliferation (9) . During this work, we also found that supernatants from splenocytes activated by M. arthritidis exhibited weak cytotoxic effects, suggesting the presence of a lymphotoxin.
Suppression induced by MAM might also be mediated by a soluble suppressor factor. Antigen-specific suppressor factors have been well documented (23, 33) , as have the nonspecific factors generated by ConA-induced suppressor cells (29, 30) ConA mediates suppression by activation of CD4-CD8+ T cells. In contrast, MAM-induced suppression appears to be mediated by a CD4+ CD8-T-helper subset since CD4 MAb and complement treatment of suppressor cells abolished their ability to inhibit mitogen responses of normal lymphocytes. CD8 MAb and complement was ineffective in abrogating suppressor activity. Our observation that thymocytes failed to develop significant suppressor activity is consistent with the suppressor cell population being a mature CD4+ cell. Recent reviews by Bottomly (5) and Mosman and Coffman (28) described growing evidence for the existence of two subsets of CD4+ CD8-murine T-helper cells, termed THi and TH2 cells. THi or "inflammatory cells" produce interleukin-2, gamma interferon, and lymphotoxin upon stimulation. These cells also participate in delayed-type hypersensitivity responses, exhibit cytotoxic properties, and can also mediate suppression of antibody responses. In contrast, TH2 cells fail to produce interleukin-2, gamma interferon, or lymphotoxin but characteristically produce interleukin-4 and supply B-cell help. The properties of MAM-responsive cells most closely resemble THi cells in their production of interleukin-2, gamma interferon, and lymphotoxin and cytotoxic activities (1, 16, 25, 36) . In addition, we have recently demonstrated that MAM induces a transient inflammatory response when administered intraarticularly into rats (6) . arthritidis is abnormal in that neutralizing, growth-inhibiting, metabolic-inhibiting, and opsonizing antibodies either fail to develop or are produced only in low titer (20) . These antibodies are produced by rodents in response to other nonmurine mycoplasma species, and M. arthritidis is capable of evoking these antibodies when injected into guinea pigs and rabbits (20) . There is also evidence that infection with M. arthritidis can directly suppress the induction of humoral antibodies to other antigens (24) . We have also documented that M. arthritidis can inhibit the in vivo interferon response of mice to viral challenge (13) . Studies are now being conducted to determine whether MAM is responsible for these suppressive effects on immune functions.
MAM may also contribute to the pathogenesis of M. arthritidis-mediated disease. We demonstrated that MAMresponsive mouse strains develop a toxic syndrome after injection with M. arthritidis which is not seen in congenic MAM-nonresponsive strains (17) . Furthermore, M. arthritidis organisms are cleared from the peripheral circulation more slowly in MAM-responsive mouse strains than in congenic MAM-nonresponsive strains. Further studies indicated that M. arthritidis induced severe necrotic lesions when injected subcutaneously into MAM-responsive mouse strains, yet produced only encapsulated abscesses when administered to congenic MAM-nonresponsive mouse strains (14) . These studies suggest that MAM indeed plays a role in the disease pathology induced by M. arthritidis and that this process is mediated by rendering the host more susceptible to invasion by the organisms by virtue of the immunosuppressive property of MAM.
It remains to be established whether the suppressive effects of MAM on murine T-cell functions have any clinical application. It should be noted, however, that the human HLA.DR molecule is the equivalent of the murine I-E molecule and that MAM induces proliferation of and interferon induction by human lymphocytes (15, 22, 27) .
Susceptibility to human disease has been clearly linked to expression of MHC and non-MHC genes which code for lymphoid cell surface proteins. We propose that M. arthritidis infection offers a unique model to study the genetic influence of MHC (Ea) and non-MHC (T-cell receptor) gene products in disease pathogenesis.
